CTLA4 and autoimmune thrombocytopenic purpura: A further study demonstrated that low-dose HDAC inhibitor can modulate CTLA-4 expression to facilitate the natural production of Foxp3+ Treg cells and restore the suppressive function of Treg cells via the regulation of histone H3K27 acetylation in immune thrombocytopenia (ITP).